T1G3 high-risk NMIBC (non-muscle invasive bladder cancer): conservative treatment versus immediate cystectomy

[11] van der Meijden APM(2010)What is the optimal treatment strategy fo T1 bladder tumors? Eur Urol 57 32-34

[12] Oosterlinck W(2000)Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer Cochrane Database Syst Rev 4 CD001986-95

[13] Witjes JA(2003)Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 90-409

[14] Raj GV(1996)A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma J Urol 156 372-686

[15] Herr H(2005)Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906) J Urol 173 405-1129

[16] Serio AM(2004)Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression Urology 63 682-434

[17] Donat SM(2000)Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 1124-70

[18] Bochner BH(2003)Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial Eur Urol 44 429-824

[19] Vickers AJ(2010)An update critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previosly T1G3) bladder cancer Eur Urol 57 60-41

[20] Dalbagni G(2002)Impact of second transurethral resection on the staging of T1 bladder cancer Urology 60 822-675

[11] van der Meijden APM(2010)What is the optimal treatment strategy fo T1 bladder tumors? Eur Urol 57 32-34

[12] Oosterlinck W(2000)Intravesical bacillus Calmette-Guerin in Ta and T1 bladder cancer Cochrane Database Syst Rev 4 CD001986-95

[13] Witjes JA(2003)Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity J Urol 169 90-409

[14] Raj GV(1996)A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma J Urol 156 372-686

[15] Herr H(2005)Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906) J Urol 173 405-1129

[16] Serio AM(2004)Intravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression Urology 63 682-434

[17] Donat SM(2000)Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study J Urol 163 1124-70

[18] Bochner BH(2003)Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial Eur Urol 44 429-824

[19] Vickers AJ(2010)An update critical analysis of the treatment strategy for newly diagnosed high-grade T1 (previosly T1G3) bladder cancer Eur Urol 57 60-41

[20] Dalbagni G(2002)Impact of second transurethral resection on the staging of T1 bladder cancer Urology 60 822-675